$GILD Recent Headlines Long view on stocks is best

New Post Public Reply Private Reply Replies (0) Message Board

Apr 21, 2014 at 9:57 AM

$GILD Recent Headlines

Long view on stocks is best during weak earnings season 6:00 a.m. April 20, 2014 - Wallace Witkowski
UnitedHealth already seeing effects of Gilead's pricey hepatitis C drug 5:54 p.m. April 17, 2014 - blogs.marketwatch.com
4 reasons the first quarter was better than it appeared 6:20 a.m. April 17, 2014 - Tim Clift
Nasdaq pummeled in worst day since 2011 as tech, biotech cave (Stock market live blog recap) 4:53 p.m. April 10, 2014 - blogs.marketwatch.com
TripAdvisor, Tesla sink as momentum plays lose favor 4:36 p.m. April 10, 2014 - Saumya Vaishampayan
Biotech hammered as ETFs down 5%, while some stocks fall 10% 1:55 p.m. April 10, 2014 - blogs.marketwatch.com
Merck: Hepatitis C drug has 98% cure rate in trial 11:43 a.m. April 10, 2014 - MarketWatch.com
Toss these investments as part of spring cleaning 6:00 a.m. April 10, 2014 - Jeff Reeves
First Solar tops S&P 500; Alcoa up ahead of earnings 3:51 p.m. April 8, 2014 - Ben Eisen
Gilead hepatitis C drug to get FDA priority review 9:40 a.m. April 7, 2014 - MarketWatch.com
Gilead: Hepatitis C Japan trial meets endpoint 3:43 a.m. April 3, 2014 - MarketWatch.com
Facebook, Biogen, Cal-Maine are stocks to watch 5:21 a.m. March 31, 2014 - Victor Reklaitis
Play-it-safe stock investors may take some risk on jobs 8:30 a.m. March 30, 2014 - Wallace Witkowski
U.S. stocks end week with losses 7:17 p.m. March 28, 2014 - Anora Mahmudova
Bombora watch, the 'momo' chart of pain and 5 reasons to buy Citigroup 8:33 a.m. March 28, 2014 - blogs.marketwatch.com
Nasdaq pullback rife with opportunity 2:07 p.m. March 25, 2014 - The Trading Deck
Biotech comeback stalls as Wall Street starts to worry 12:45 p.m. March 25, 2014 - blogs.marketwatch.com
Nasdaq slumps 1.2%, but Dow dips just 0.2%: Stock market live blog recap 3:39 p.m. March 24, 2014 - blogs.marketwatch.com
Biotech has second straight sell-off; sector mutual funds take it on chin 10:40 a.m. March 24, 2014 - blogs.marketwatch.com
Biotech's Friday selloff: Are sector bears growling or just stretching? 5:08 p.m. March 21, 2014 - blogs.marketwatch.com

J.P. Morgan’s Top Biotech and Health Care Picks With Huge Upside 8:39 a.m. Today - 247WallSt.com
Weekly Insider Sells Highlight: ATHN, GILD, JPM, WAG 10:06 p.m. April 20, 2014 - GuruFocus.com
Excellent Earnings, Tough Audience, Surprises Among the Leaders: Jim Cramer's Best Blogs 6:00 a.m. April 19, 2014 - TheStreet.com
Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings 11:12 a.m. April 18, 2014 - Investors Business Daily
UnitedHealth Earnings Drop on ObamaCare, Medicare Cuts 5:13 p.m. April 17, 2014 - Investors Business Daily
Has A Streamlined FDA Raised The Value Of Drug Stocks? 4:33 p.m. April 17, 2014 - Investors Business Daily
After Shaky Start, Weibo Jumps in Nasdaq Debut 4:00 p.m. April 17, 2014 - FOXBusiness
Today's Top Performers In Drugs 1:03 p.m. April 17, 2014 - TheStreet.com
UnitedHealth's Profit Falls Amid Health-Law Changes 11:33 a.m. April 17, 2014 - The Wall Street Journal Interactive Edition
Managers See Buys in Choppy Markets, Including Gilead, LinkedIn 9:41 a.m. April 17, 2014 - TheStreet.com
Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings 9:18 a.m. April 17, 2014 - TheStreet.com
Ready For A Rebound? Gilead's $1000 Pill 7:38 a.m. April 17, 2014 - Seeking Alpha
Biggest Movers in Healthcare Stocks Now – ALXN MRK GILD XRAY 7:30 a.m. April 17, 2014 - InvestorPlace.com
Rolling The Dice With Earnings 5:29 p.m. April 16, 2014 - Seeking Alpha
3 Stocks Reiterated As A Buy: EBAY, GS, GILD 3:14 p.m. April 16, 2014 - TheStreet.com
Gilead Sciences May See A Healthy Earnings Beat 1:35 p.m. April 16, 2014 - Seeking Alpha
IPOs: 4 Stocks To Buy After The Plunge 10:08 a.m. April 16, 2014 - InvestorPlace.com
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog 10:07 a.m. April 16, 2014 - Zacks.com
Why Gilead Sciences Inc. (GILD) Stock Might be a Great Pick - Tale of the Tape 8:32 a.m. April 16, 2014 - Zacks.com
3 Pharmaceuticals to Profit on Obamacare 6:34 a.m. April 16, 2014 - InvestorPlace.com

Young Scientists From Around the State Will Compete for Top Honors at the 63rd California State Science Fair 6:31 p.m. April 16, 2014 - PR Newswire - PRF
Gilead Sciences to Release First Quarter 2014 Financial Results on Tuesday, April 22, 2014 5:00 p.m. April 15, 2014 - BusinessWire - BZX
AHF: Anti-Gilead Drug Pricing Campaign Picks Up Steam 2:24 p.m. April 14, 2014 - BusinessWire - BZX
Financial Release Dates -- Research on Gilead Sciences, Juniper Networks, FirstCommonwealth Financial, and Genuine Parts 9:00 a.m. April 14, 2014 - PR Newswire - PRF
Final Data from the Phase 2 COSMOS Study of Janssen’s Once-Daily Simeprevir in Combination with Sofosbuvir Presented at the International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL) 11:24 a.m. April 12, 2014 - BusinessWire - BZX
Final Data from the Phase 2 COSMOS Study of Janssen's Once-Daily Simeprevir in Combination with Sofosbuvir Presented at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL) 11:15 a.m. April 12, 2014 - PR Newswire - PRF
Final Data from the Phase 2 COSMOS Study of Janssen's Once-Daily Simeprevir in Combination with Sofosbuvir Presented at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL) 11:15 a.m. April 12, 2014 - PR Newswire - PRF
Priority Reviews, Preliminary Earnings Releases, Clinical Trials Results, and Launch of Website - Analyst Notes on Gilead, Pfizer, Intuitive Surgical, Alkermes and Quest 10:14 a.m. April 11, 2014 - PR Newswire - PRF
Today's Review on Active Stocks -- Research on Ashford Hospitality Trust, Dejour Energy, North American Palladium, and Gilead Sciences 1:30 p.m. April 10, 2014 - PR Newswire - PRF
Emerging Therapies in Development for Relapsed/Refractory CLL/SLL are Expected to Offer Efficacy Benefits Over Currently Available Treatments 10:00 a.m. April 10, 2014 - PR Newswire - PRF
Gilead Announces Phase 2 Results for Two Investigational All-Oral Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C 1:02 a.m. April 10, 2014 - BusinessWire - BZX
Clinical Trial Results Presentation and Publication, and Upcoming Exhibit - Analyst Notes on Gilead Sciences, Agios, Mindray, BG Medicine, and Ultragenyx 8:00 a.m. April 9, 2014 - PR Newswire - PRF
Gilead Announces U.S. FDA Priority Review Designation for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Chronic Hepatitis C Genotype 1 Infection 8:31 a.m. April 7, 2014 - BusinessWire - BZX
Senior Notes Conversions, FDA Drug Approvals, Acquisitions, Stock Price Updates, and Clinical Trial Studies - Analyst Notes on Gilead, Pfizer, Nordion, Intuitive Surgical, and Novartis 8:00 a.m. April 3, 2014 - PR Newswire - PRF
Gilead Announces Results From Phase 3 Study of Sofosbuvir Among Hepatitis C Patients in Japan 4:30 p.m. April 2, 2014 - BusinessWire - BZX
Critical Alerts For Ford, Castlight Health, Gilead Sciences, Take Two Interactive, and Qihoo 360 Released By InvestorsObserver 9:31 a.m. April 2, 2014 - PR Newswire - PRF
Pending Applications, Closed Public Offering, Joint Venture Formation, Executive Appointment, and Commercial Launch - Analyst Notes on Gilead, Enzymotec, Intrexon, Advaxis, and Repligen 8:00 a.m. April 1, 2014 - PR Newswire - PRF
Comprehensive Technical Coverage on Active Equities -- Research on Sirius XM, Gilead Sciences, Microsoft, and Yahoo! 12:03 p.m. March 31, 2014 - PR Newswire - PRF
Gilead Announces Settlement Method for 1.00% Convertible Senior Notes Due 2014 8:30 a.m. March 28, 2014 - BusinessWire - BZX
Gilead's Marketing Application Validated by EMA; Accenture Misses Zack's Consensus Estimate 12:38 a.m. March 28, 2014 - ACCESSWIRE

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SlidesAI Launches Standalone Platform for Presentations

From Add-on to Standalone: SlidesAI's Big Leap You know what they say: time waits for no one, and that seems true in tech too. Those suit-and-tie presentation days? SlidesAI just took a swing at redefining them. Once a trusty sidekick locked into Google Slides, it's now captaining its own ship. Welcome to the SlidesAI standalone presentation platform—where AI meets your...

Investors Slam Coastal Financial: Class Action Looms Large

The air's thick with tension as Coastal Financial Corporation (NASDAQ:CCB) finds itself embroiled in a securities class action lawsuit. Investors who grabbed shares between October 28, 2024, and July 29, 2026, are in the spotlight and urging those with losses to make a move by the December 1, 2026, lead plaintiff deadline. Sounds like a real mess, doesn't it? Well, it's a...

Synova Global Taps Eventus for Top Trade Surveillance

Synova and Eventus: A Powerful Partnership If you've ever traded a share or two, you know the name of the game is risk management. Step into Synova Global's latest move, and you'll see a gamble worth watching closely. This time around, Synova has tapped Eventus to bring their Validus trade surveillance platform into the fold. Now, Eventus and its star player, Validus,...

RideNow Gears Up for Earnings Amidst Industry Shifts

Highway to Earnings: RideNow's Third Quarter Call Alright, folks, this is the moment the powersports crowd has been itching for. RideNow Group, Inc. (NASDAQ: RDNW) is set to roll out their third-quarter financial results on November 10, 2026. If you're in for a wild ride—pun fully intended—mark this on your calendars. With this company hogging the spotlight in the...

Swif.ai Paves Linux Path for Enterprise Developers

The Quiet Revolution: Linux Takes Center Stage Linux, once the underdog of operating systems, is gaining significant traction in the world of AI development. It's not just a nerd's sandbox anymore; it's rapidly becoming the go-to platform for cutting-edge AI innovation. Now, more enterprise IT departments are facing the choice of keeping up with Linux's popularity—or...

PG&E, Edison Push Liability Cap Amid Firestorm

The Thanksgiving Playbook Nobody Wanted Sacramento's corridors are buzzing with electric tension. And why? It's not some trivial turkey drama but a simmering scandal over two utility giants trying to sneak a liability cap into law faster than you can ask for a second slice of pumpkin pie. PG&E and Edison have a little secret—a covert strategy to limit shareholder...

Staypineapple Backs Vets: A Heartwarming Initiative

When Hotels Stand Up for Heroes Every now and then, you stumble upon a company doing something genuinely good, and Staypineapple's effort this November is one of those rare gems. In honor of Veterans Day, they're opening their checkbook to sling some real support to our nation’s vets and retired first responders. Their chosen cause? The American Humane Society's...

Viatris Declares Quarterly Dividend Amid Acquisition Buzz

A Dividend Declaration with a Side of Mergers Viatris, the healthcare giant operating on a global scale, has been making some noise recently. On the surface, it's another quarterly dividend—$0.12 per share, set to hit the pockets of shareholders on December 16. But there's a lot more cooking under the hood of this announcement that ticks just about every box for a...

LITE, RRC, SGRY: Are Shareholders Getting Shortchanged?

What's Really Going On Here? Here's the skinny: Halper Sadeh LLC, that hard-hitting investor rights law firm, is poking their noses into some potential red flags over at a few companies you might have heard of—Lumentum Holdings (NASDAQ:LITE), Range Resources (NYSE:RRC), and Surgery Partners (NASDAQ:SGRY). They're sniffing around transactions that might leave the regular...

WuXi Biologics Racks Up Top Honors for ESG Excellence

WuXi Strikes Gold with ESG Distinction Take a look under the hood, and you’ll find that WuXi Biologics (2269.HK) isn’t just playing the long game—they’re redefining it. They’ve clinched not one, but two prestigious honors from the Hong Kong ESG Reporting Awards (HERA). And with sustainability in the hot seat worldwide, these wins are no small potatoes. They...